Dr Reddy's Laboratories on Wednesday reported a 1% increase in consolidated net profit to ₹1,410 crore during the June quarter.
The Hyderabad-based drug major reported a net profit of ₹1,392 crore in the year-ago period.
Revenue increased to ₹8,545 crore in he period under review from ₹7,673 crore a year earlier.
"We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," Dr Reddy's Co-Chairman & MD G V Prasad said.
The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted.
"We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad said.
Shares of the company ended 0.58% up at ₹1,247.55 apiece on the BSE
